Pitch Introduction
The Vibrasense Shark Tank India pitch introduced a critical medical innovation designed to tackle one of the most devastating complications of diabetes: foot amputations. Founder Nishant Katpa presented his startup, Ayati Devices, which manufactures portable, handheld diagnostic tools that can detect nerve damage in diabetic patients within minutes. With India being labeled the ‘diabetes capital of the world,’ the need for accessible neuropathy testing has never been higher. Nishant entered the tank seeking ₹1 Crore for 2% equity, valuing his life-saving venture at ₹50 Crores.
Business Overview
Ayati Devices, the parent company of Vibrasense, focuses on creating medical-grade diagnostic equipment that is both affordable and portable. The primary problem they solve is the lack of early detection for diabetic neuropathy. In many cases, diabetes patients lose sensation in their feet due to nerve damage, which leads to undetected injuries, ulcers, gangrene, and eventually, amputation. Traditional gold-standard tests like Nerve Conduction Studies are expensive (costing up to ₹10,000) and are mostly restricted to Tier-1 hospitals.
Vibrasense bridges this gap by providing a portable alternative that primary care physicians can use in their clinics. The device uses a quantified vibration stimulus to determine the ‘Vibration Perception Threshold’ (VPT). By measuring at what level a patient starts feeling the vibration, doctors can categorize the nerve damage as mild, moderate, or severe. This allows for early intervention, which can prevent up to 85% of amputations globally.
Product Details
The company offers a suite of products tailored for different stages of diabetic foot care. The flagship product is Vibrasense, a battery-powered device that can test over 100 patients on a single charge. It provides a digital report that tracks patient progress over time. For more advanced cases, they developed Vibrasense+, which includes thermal (hot and cold) sensation testing to assess small nerve fiber damage. Their third product, Angio Cam, uses laser speckle contrast imaging to quantify blood flow in an injury, helping doctors predict if a wound will heal or require surgical intervention.
Market Position
Vibrasense holds a unique position in the Indian medical device market as a Make in India patented product. While traditional subjective tests like the monofilament test have only 30-50% sensitivity, Vibrasense boasts a sensitivity of over 80%. It competes against bulky, non-portable ‘Bio-Thesiometers’ that require dedicated rooms and technicians. By miniaturizing this technology into a handheld wand, Ayati Devices has made it possible for any local doctor to perform a high-quality neuropathy screening for a fraction of the cost.
| Business Detail | Information |
|---|---|
| Company Name | Ayati Devices (Vibrasense) |
| Founder | Nishant Katpa |
| Product Type | Medical Diagnostic Device |
| Price Range | ₹15,000 – ₹25,000 |
| Primary Channel | Pharma B2B & Direct to Doctors |
| Headquarters | Sonipat, Haryana |
About Founder’s
Nishant Katpa, the visionary behind Ayati Devices, hails from Sonipat, Haryana. He completed his graduation in Electronics and Communication before pursuing an M.Tech in VLSI and Embedded Systems at IIT Bombay. It was during a collaborative engineering course at IIT Bombay—where engineers and doctors work together—that Nishant encountered the problem of diabetic foot amputations. According to his YourStory feature, the personal motivation hit home when he discovered three of his own family members were suffering from severe diabetic neuropathy.
- Incubated at IIT Bombay (SINE) in 2019.
- Secured ₹50 Lakhs in initial government grants to develop the prototype.
- Developed four patented technologies for precise stimulus delivery.
- Relocated operations to Bangalore to tap into the medical tech ecosystem.
Shark’s and Founder’s QnA
Nishant, can you explain what exactly this device does differently from a standard nerve test?
The gold standard is a nerve conduction study, but it is expensive and takes 40-60 minutes. We have quantified the loss of sensation through vibration. We generate a controlled stimulus and record the exact point a patient feels it. This creates a quantifiable data point, unlike the qualitative nylon thread tests doctors usually do, which are very subjective.
How many units have you sold and who are your primary customers?
We have sold more than 4,000 units so far across 15+ countries. Currently, about 85% of our sales come from pharmaceutical companies who buy these devices for their diagnostic camps. The remaining 10-15% are direct sales to individual doctors and neurologists. We are now looking to expand the direct doctor-sales model significantly.
What is the price point of the device and do you have recurring revenue?
The device sells for between ₹15,000 to ₹25,000 depending on the volume. For international distributors, it is around $100 to $200. Currently, it is a one-time hardware sale, but we are planning to transition into a software-as-a-service (SaaS) model where we charge for the reporting and data analytics side in the long run.
You mentioned you are EBITDA positive. What was your revenue last year?
In the last financial year, we closed at ₹2.3 Crores. Before that, it was ₹1.75 Crores and ₹1.3 Crores the year before that. We have been growing steadily while staying profitable at the operational level. We have used about ₹9 Crores in total funding so far, including grants and angel rounds.
Do you have patents for this technology?
Yes, we have four patents in total, and two of them have already been granted. The patent covers the technology of how the device provides a consistent stimulus despite negative feedback, ensuring that every test is accurate and repeatable regardless of how the probe is held against the skin.
Peyush, you seem concerned about the lack of direct doctor sales. Why is that?
My issue is that in several years, you haven’t cracked the doctor market deeply. While pharma sales are good, a sustainable medical device company needs doctors to buy it as a core part of their practice. I also wonder if there are other technologies that could track blood flow or glucose levels through vision, which would be a bigger game-changer.
Key Stats & Financials
Vibrasense demonstrated a strong financial track record for a hardware startup in the medical space. The company has maintained a positive EBITDA while scaling its manufacturing capabilities in Bangalore. At the time of the pitch, the brand was generating significant revenue from the pharmaceutical sector, leveraging B2B partnerships to achieve scale without a massive direct-to-consumer marketing spend.
Revenue and Profitability
- Lifetime Sales: Over ₹6 Crores in cumulative revenue.
- Profit Margins: EBITDA positive; healthy gross margins on hardware.
- Valuation: Requested ₹50 Crores; Deal closed at ₹21 Crores.
- Investment Request: ₹1 Crore for 2% equity.
- Customer Acquisition: Primarily through pharma B2B channels and doctor leads.
Financial Breakdown
| Metric | Amount / Value |
|---|---|
| FY 2023-24 Revenue | ₹2.3 Crores |
| FY 2022-23 Revenue | ₹1.75 Crores | ₹1.3 Crores |
| Total Funding Raised | ₹9 Crores |
| Device Retail Price | ₹25,000 |
| Units Sold | 4,000+ |
Business Potential and TAM
The Total Addressable Market (TAM) for Vibrasense is massive, driven by the global diabetes epidemic. There are currently over 500 million people living with diabetes worldwide, and that number is projected to rise significantly in the coming decades. In India alone, there are 100 million recorded diabetic patients. Research indicates that 50% of these patients will develop some form of neuropathy in their lifetime, and 25% will suffer from foot ulcers. With 2 to 3 Lakh amputations occurring annually in India, the market for preventive diagnostic tools is virtually untapped.
Market Size Analysis
The global diabetic foot ulcers market is valued at approximately $9 Billion and is growing at a CAGR of 6.5%. The diagnostic segment, which includes neuropathy screening, is a multi-billion dollar opportunity. By focusing on Tier-2 and Tier-3 cities where high-end diagnostic infrastructure is missing, Vibrasense can capture the primary care market. If they can penetrate just 10% of the clinics in India, the revenue potential exceeds ₹500 Crores annually.
Growth Opportunities
- International Expansion: Moving into insurance-driven markets like the USA and EU where diagnostic reimbursement is high.
- SaaS Integration: Developing a subscription model for AI-based risk prediction and patient data management.
- Pharma Partnerships: Scaling from 8 pharma companies to the 120+ companies manufacturing neuropathy drugs in India.
- Product Diversification: Launching Angio Cam for vascular health monitoring in diabetic clinics.
Vibrasense: Ideal Target Audience & Demographics
| Demographic | Details |
|---|---|
| Primary Age Group | 45 to 75 Years |
| Secondary Age Group | Medical Professionals (MBBS, Diabetologists) |
| Interests | Healthcare, Diabetes Management, Med-Tech |
| Platform Preference | LinkedIn, Medical Journals, Pharma Conferences |
| Geography | India (Focus on Tier 2/3), SE Asia, Africa |
| Buying Behavior | B2B Institutional Sales & Professional CapEx |
Marketing and Distribution Strategy
Ayati Devices employs a dual marketing strategy that balances volume and brand authority. By partnering with pharmaceutical companies, they gain instant access to thousands of doctors. Pharma companies use these devices to provide free screenings to patients, which in turn leads to higher prescriptions for their neuropathy medications. This symbiotic relationship has been the primary engine of growth for Vibrasense.
Customer Acquisition
The cost of acquiring a doctor as a direct customer is relatively high due to the need for physical demos. However, the company is shifting towards a lead-generation model through medical conferences and digital marketing on professional platforms. Their CAC is optimized by leveraging the pharma sales force, which acts as a third-party distribution channel for the hardware.
Distribution Channels
- Pharmaceutical B2B: Bulk sales for diagnostic camps and doctor gifting.
- Medical Distributors: Regional partners selling to Tier-2 and Tier-3 private clinics.
- Direct-to-Institution: Selling to large hospital chains and government NGOs.
- Export: Distributors in Southeast Asia and Middle Eastern markets.
Social Media and Content Strategy
Vibrasense focuses its content on educational awareness. They produce case studies showing how early detection saved limbs and use LinkedIn to connect with key opinion leaders (KOLs) in the diabetes space. Their social media presence is professional and clinical, targeting healthcare decision-makers rather than the end patient.
Vibrasense Shark Tank Deal Outcome
The negotiation for Vibrasense was intense, with Sharks debating the scalability of the business model. While Anupam Mittal and Aman Gupta were impressed by the technology but concerned about market penetration, Namita Thapar saw an immediate synergy with her pharmaceutical expertise. Peyush Bansal also saw the long-term impact potential. Eventually, the duo offered ₹1 Crore for 4.76% equity, which Nishant accepted.
| Shark | Offer Detail |
|---|---|
| Namita Thapar | Offered ₹50 Lakhs for 2.38% equity (Joint Deal) |
| Peyush Bansal | Offered ₹50 Lakhs for 2.38% equity (Joint Deal) |
| Anupam Mittal | Out – Felt the business was too early for his thesis |
| Vineeta Singh | Out – Cited concerns over hardware scalability hurdles |
| Final Decision | Accepted ₹1 Crore for 4.76% equity |
Vibrasense Post-Show Update
Since the pitch aired, Ayati Devices has focused on scaling its international presence. According to reports from YourStory, the company has ramped up production at its Bangalore facility and is seeking regulatory approvals for Western markets. The partnership with Namita Thapar is expected to open doors to dozens of new pharmaceutical partners, while Peyush Bansal‘s expertise in hardware distribution will assist in cracking the direct-to-doctor retail model. Verified post-show revenue figures for 2025 are not yet available, but the company aims to triple its installation base by the end of the year.
Business Analysis & Lessons
The Vibrasense pitch is a classic example of a high-impact, ‘deep-tech’ medical startup that balances social good with profitability. Nishant’s ability to demonstrate a working, patented device that solves a massive pain point made the valuation argument easier, even if the Sharks eventually negotiated a higher equity stake. The business model’s reliance on pharma companies is a clever ‘Trojan Horse’ strategy to gain market entry while building the infrastructure for direct sales.
One of the primary challenges identified was ‘feature creep’—developing too many products (Angio Cam, Vibrasense+) before fully dominating the market with the flagship device. However, the IP protection and the founder’s academic pedigree from IIT Bombay provided the Sharks with the confidence that the technical foundation of the company is rock solid.
Key Takeaways
- IP is Power: Having four patents in a crowded medical field provided a significant competitive moat.
- B2B as a Bridge: Using pharma companies for distribution solves the problem of a small startup having a limited sales force.
- Personal Connection: Nishant’s family history with diabetes added emotional weight and credibility to his mission.
- Data over Hardware: The real value of the company lies in the longitudinal patient data they collect, paving the way for a future SaaS valuation.
Pitch Conclusion
The Vibrasense Shark Tank India journey concluded with a strong partnership that combines medical distribution power with hardware scaling expertise. By securing ₹1 Crore, Ayati Devices is well-positioned to lead the charge against diabetic amputations in India and beyond. If you enjoyed this breakdown, check out CureSee, MeduLance, and Neuphony.
[faq_accordian]